Kerri Fitzgerald

DocwireNews

Belantamab mafodotin, an investigational <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/developing-a-novel-anti-bcma-car-t-for-relapsed-or-refractory-multiple-myeloma/">anti-B-cell maturation antigen monoclonal antibody</a>-drug conjugate, demonstrated anti-myeloma activity in patients with relapsed/refractory <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/this-multiple-myeloma-drug-is-gaining-traction-despite-costs/">multiple myeloma</a> (MM), according to a study published in The Lancet Oncology.The open-label, two-arm, randomized, phase II, ongoing DREAMM-2 study was conducted at 58 MM specialty centers in eight countries and included adult patients with relapsed/refractory MM that had progressed after three or more lines of therapy and who were refractory to immunomodulatory drugs and proteasome inhibitors and refractory and/or intolerant to an anti-CD38 monoclonal antibody. Patients had an Eastern Cooperative Oncology Group performance status score of 0-2 and were stratified based on prior lines of therapy (&le;4&nbsp;vs.&nbsp;&gt;4) and cytogenetic features.Between June 18, 2018, and Jan 2, 2019, 293 patients were randomized 1:1 to receive belantamab mafodotin 2.5 mg/kg (n=97) or 3.4 mg/kg (n=99) intravenously every three weeks on day one of each cycle until disease progression or unacceptable toxicity.<h2>Response observed in approximately one-third of patients</h2>At primary analysis cutoff (June 21, 2019), 30 patients (31%; median age, 65 years) in the 2.5 mg/kg cohort and 34 patients (34%; median age, 67 years) in the 3.4 mg/kg cohort achieved an overall response (primary endpoint). Median duration of response was not yet reached at a median follow-up of 6.3 months in the 2.5 mg/kg group and 6.9 months (IQR, 4.8-7.9) in the 3.4 mg/kg group.Overall survival data were not mature at the time of analysis. The median progression-free survival was 2.9 months in the 2.5 mg/kg group and 4.9 months in the 3.4 mg/kg group.The most common grade 3/4 adverse events (AEs) associated with belantamab mafodotin 2.5 mg/kg and 3.4 mg/kg included keratopathy (27% vs. 21%), thrombocytopenia (20% vs. 33%), and anemia (20% vs. 25%). Serious AEs occurred in 38 patients (40%) in the 2.5 mg/kg cohort and 47 patients (47%) in the 3.4 mg/kg cohort.A total of 32 deaths occurred in the 2.5 mg/kg group and 31 deaths occurred in the 3.4 mg/kg group. Two deaths were potentially related to treatment: sepsis in the 2.5 mg/kg cohort and hemophagocytic lymphohistiocytosis in the 3.4 mg/kg cohort.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

A New Anti-BCMA Therapy for Multiple Myeloma

Oncology

Belantamab mafodotin, an investigational anti-B-cell maturation antigen monoclonal antibody-drug conjugate, demonstrated anti-myeloma activity in patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe